Aflibercept (Eylea) is indicated for the treatment of: neovascular (wet) age-related macular degeneration (wet AMD), macular edema secondary to central retinal vein occlusion (CRVO), macular edema secondary to branch retinal vein occlusion (BRVO), diabetic macular edema (DME), myopic choroidal neovascularization (myopic CNV).